Does Emtricitabine And Tenofovir Disoproxil Fumarate Interact with Ritonavir?
CDI records a major classification for Emtricitabine And Tenofovir Disoproxil Fumarate and Ritonavir. The stored summary is: Coadministration of TRUVADA with certain HIV-1 protease inhibitors including ritonavir increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. The mechanism involves increased tenofovir concentration. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Emtricitabine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Ritonavir Class
- Cytochrome P450 3A Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increased tenofovir concentration
What To Tell Your Doctor or Pharmacist
If you are taking Emtricitabine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Ritonavir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider